The Director Global Market Access & Pricing role for frexalimab contributes to pricing and market access strategy and execution across the RMS and nrSPMS indications. Frexalimab is a potential first-in-class anti-CD40L antibody, with a Phase 3 program underway. Multiple sclerosis is expected to be the first indication in a broader program spanning immunology and metabolic diseases, and strategic decisions made for MS may shape future indications. The role sits within the Global Market Access & Pricing Neurology Team in Specialty Care Global Market Access. It partners across Commercial, Medical, Clinical, Evidence for Access, Global Pricing, Biostatistics, Regulatory Affairs, Public Affairs, and country teams to support timely patient access and value recognition by external stakeholders, including payers. The position is based in Cambridge, Massachusetts.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director